Suppr超能文献

通过葡萄糖醛酸化消除活性他莫昔芬代谢物的抗雌激素作用。

Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.

作者信息

Zheng Yan, Sun Dongxiao, Sharma Arun K, Chen Gang, Amin Shantu, Lazarus Philip

机构信息

Cancer Prevention and Control, Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.

出版信息

Drug Metab Dispos. 2007 Oct;35(10):1942-8. doi: 10.1124/dmd.107.016279. Epub 2007 Jul 9.

Abstract

1-[4-(2-Dimethylaminoethoxy)-phenyl]-1,2-diphenylbut-1-(Z)-ene (tamoxifen, TAM) is a nonsteroidal antiestrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-hydroxy-TAM (4-OH-TAM) and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. Whereas high antiestrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the antiestrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive progesterone receptor (PGR) gene. 17beta-Estradiol (E(2))-mediated PGR gene expression in MCF-7 cells was determined by real-time reverse transcriptase-polymerase chain reaction for each TAM metabolite isomer. E(2) (1 x 10(-10) M) induction of PGR mRNA was 6-fold after a 12-h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E(2)-induced PGR gene expression was found for both the trans- and cis-isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 x 10(-6) M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E(2)-mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent antiestrogenic effects on E(2)-induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This result may have important implications in terms of both whole-body and target tissue-specific glucuronidation pathways and individual responses to TAM therapy and cancer prevention.

摘要

1-[4-(2-二甲基氨基乙氧基)-苯基]-1,2-二苯基丁-1-(Z)-烯(他莫昔芬,TAM)是一种非甾体类抗雌激素药物,常用于预防和治疗雌激素受体阳性乳腺癌。TAM会广泛代谢为几种主要活性代谢产物,包括4-羟基-TAM(4-OH-TAM)和内昔芬。葡萄糖醛酸化是其排泄过程中重要的II相代谢途径。虽然已有报道称4-OH-TAM和内昔芬均具有高抗雌激素活性,但此前尚未进行过关于这些代谢产物葡萄糖醛酸结合作用影响的研究。在本研究中,通过检测葡萄糖醛酸化TAM代谢产物对雌激素反应性孕激素受体(PGR)基因诱导的影响,来确定其抗雌激素活性。通过实时逆转录聚合酶链反应,针对每种TAM代谢产物异构体,测定MCF-7细胞中17β-雌二醇(E₂)介导的PGR基因表达。E₂(1×10⁻¹⁰ M)孵育12小时后,PGR mRNA的诱导倍数为6倍;只有未结合的TAM代谢产物能抑制这种作用。对于4-OH-TAM和内昔芬的反式和顺式异构体,均发现对E₂诱导的PGR基因表达有几乎相同的剂量依赖性抑制作用,在1×10⁻⁶ M的TAM代谢产物时达到最大抑制。在本研究检测的所有TAM代谢产物浓度下,所有4-OH-TAM和内昔芬异构体的葡萄糖醛酸结合物对E₂介导的PGR表达诱导均无影响。这些数据表明,4-OH-TAM和内昔芬的异构体对E₂诱导的基因表达表现出大致相当的抗雌激素作用,并且相同代谢产物的葡萄糖醛酸结合物有效地消除了这种活性。这一结果可能对全身和靶组织特异性葡萄糖醛酸化途径以及个体对TAM治疗和癌症预防的反应具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验